NeOnc Technologies Holdings Inc. (Nasdaq: NTHI) announced newly published preclinical findings from a research collaboration at the University of Southern California. The study, now available on bioRxiv, indicates that the use of ultrasound enhances the therapeutic potency of NEO100 in treating primary and metastatic brain tumors. The research utilized an AI-driven, 3D-bioprinted methodology to rapidly generate patient-derived tumor organoids and demonstrated strong antitumor effects when NEO100 was combined with ultrasound. The results have already been presented through publication on bioRxiv.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neonc Technologies Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001829126-25-009754), on December 05, 2025, and is solely responsible for the information contained therein.